A new era of oral anticoagulants is upon us. Oral anticoagulants such as dabigatran, rivaroxaban and apixiban with specific action against factor Xa and thrombin are undergoing trials and process of approval through the US Food and Drug Administration (FDA). Rivaroxaban is already available in some countries outside of United States, and awaits approval in United States. Dabigatran was recently approved in the United States. These medications have indications for anticoagulation in conditions such as stroke prevention in atrial fibrillation and prevention of venous thromboembolism in hip and knee surgery patients. [1] [2] [3] It has been suggested that laboratory monitoring may not be necessary for the fixed dosages of these medication. 4 This may be of great benefit in comparison to using warfarin that requires frequent international normalized ratio (INR) checks and adjustment of dosage of warfarin based on INR values.
There is a constant challenge faced by physicians to have treatment options available to them with different routes of administration of medication to treat patients that may be acutely ill in intensive care setting or on outpatient basis. The different choices of medication available add to treatment options for both physicians and patients. While most trials are conducted in adults with conditions specific to the indication of the medication, a need for treatment options in specialized groups such as pregnant women and children continues to exist.
These medications will undoubtedly add to the complexity of patient care, as drug interactions would play a significant role. Even though laboratory monitoring of these drugs may not be necessary, a need to assess the level of anticoagulation may be of utmost importance in times of therapeutic failure of these medication and circumstances leading to the need for urgent surgery since reversal agents are not available currently. The cost of these medications would be a deciding factor for their usage by many patients. Preventing off-label use would be of significant importance as safety of medication continues to be the prime concern in this dynamic and constantly evolving field of medicine.
The impact of these medications on the standard of care approach, which includes both heparins and its derivatives and warfarin, can only be assessed upon reviewing the postmarketing surveillance data in their respective indications. It is expected that the transition in favor of these medication will be gradual for the established indications for currently used conventional anticoagulants. The relative safety and efficacy of the individual oral anticoagulant is difficult to predict in terms of superiority of the newer agent; therefore, registries and Med-Watch programs to track these parameters will be crucial in their acceptance.
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